Articles

From manufacturing to supply chain strategies, here’s how drug manufacturers are looking at the year ahead.

The company’s experience as a former RNA drug developer gives it a unique edge — it understands not just how to make RNA, but how to make it work in real-world applications.

The Indiana-headquartered pharma giant chose to make its investment announcement this week in Washington, D.C., with newly confirmed Commerce Secretary Howard Lutnick.

With a portfolio that spans first-in-human trials to commercial production, KBI is a solutions provider whose specialty is tackling the toughest molecules.

The first commercial scale “smart” factory is in New Jersey, with other integrated development and manufacturing organization facilities being built in Belgium and Japan.

This year’s outlook for the contract development and manufacturing organization market is cautiously optimistic.

CEO Greg Behar, who took Recipharm’s helm last year, has made targeted investments and divested its non-core sites to become a “more agile” company.

In 2025, Charles River’s contract development and manufacturing organization business is set to struggle, while Siegfried’s growth outlook is fueled by strong demand.

The global CDMO, in a realignment of its business operations, is withdrawing from the field of cell and gene therapy and increasing its focus on biologics.

Adhering to a tried-and-true set of best practices during the PPQ stage can prevent a drug approval from stalling out on the final lap.

While declining to comment on the specific growth strategy, a Novo Holdings spokesperson confirmed a statement provided by its senior partner to Reuters last month.

India’s Global Calcium and China’s Wuhu Nuowei Chemistry and Chengdu Innovation Pharmaceutical are the latest to be hit with warning letters from U.S. regulators.

The company sees its contract development and manufacturing organization business as poised to benefit from investments in Eurofins CDMO Alphora in Mississauga, Ontario.

The CDMO recently added a five-head isolator filler, designed for fill-finish activities, with the potential to generate up to $300 million in revenue annually.

Rising manufacturing standards, novel therapeutics, and personalized medicine demand are driving change, with large CDMOs integrating vertically and smaller ones specializing ...

President Trump has for now suspended a 25% levy on imports from Canada, but the looming tariff threat was a hot topic of discussion at a life sciences summit in Toronto.

In September, Agilent completed its acquisition of Biovectra, a contract development and manufacturing organization. Now, President Trump has threatened Canada with tariffs.

President Trump on Saturday imposed tariffs on imports from Canada, China, and Mexico. On Monday, Trump said he would pause the levies on Canada and Mexico.

Switzerland-based Lonza, the world’s largest CDMO by revenue, reported mixed full-year results this week but CEO Wolfgang Wienand promised significant growth potential ahead.

CEO Alberto Santagostino, who took the helm in November 2024, is looking to differentiate the Seattle-based company from other CDMOs targeting the biopharma industry.

The CDMO is building identical large-scale production facilities in the U.S. and Europe, designed to modularly and seamlessly integrate manufacturing regardless of location.

Just days apart, the company was hit with a Complete Response Letter and a clinical hold related to the FDA’s inspection findings at a third-party manufacturing facility.

Donald Trump’s presidency is creating a sense of optimism in the sector, as he looks to implement an America First trade agenda including tariffs on China, Canada and Mexico.

CEO Wolfgang Wienand touted the divestiture at last week’s J.P. Morgan Healthcare Conference in San Francisco. However, some in the audience expressed concerns.

This week, CEOs from Charles River, Thermo Fisher, and WuXi Biologics provided mixed outlooks for 2025 at the J.P. Morgan Healthcare Conference in San Francisco.

As CDMOs attend the J.P. Morgan Healthcare Conference in San Francisco, Jan. 13-16, analysts remain cautiously optimistic about the industry’s outlook in 2025.

The companies used Sutro Biopharma’s proprietary cell-free expression technology on a commercial scale to manufacture Sutro’s luvelta, an antibody-drug conjugate.

From biologics to treatments for rare diseases, these drugs will bring unique production challenges that require advanced technologies and precise processes.

Contrasting the fortunes of other hot drug classes, it is possible that cell and gene therapies may have reached their apex. So, where do they go next?

With China aggressively pursuing a strategy to become the world’s leader in biotech, America must invest in biomanufacturing to maintain its global dominance.